Paul Whiteaker - Publications

Affiliations: 
Pharmacology & Physiology Barrow Neurological Institute, Phoenix, AZ, United States 

96 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 George AA, John SJ, Lucero LM, Eaton JB, Jaiswal E, Christensen SB, Gajewiak J, Watkins M, Cao Y, Olivera BM, Im W, McIntosh JM, Whiteaker P. Analogs of α-conotoxin PnIC selectively inhibit α7β2- over α7-only subtype nicotinic acetylcholine receptors via a novel allosteric mechanism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 38: e23374. PMID 38161283 DOI: 10.1096/fj.202302079  0.488
2023 Whiteaker P, George AA. Discoveries and future significance of research into amyloid-beta/α7-containing nicotinic acetylcholine receptor (nAChR) interactions. Pharmacological Research. 106743. PMID 37084859 DOI: 10.1016/j.phrs.2023.106743  0.422
2022 Bavo F, Pallavicini M, Pucci S, Appiani R, Giraudo A, Oh H, Kneisley DL, Eaton B, Lucero L, Gotti C, Clementi F, Whiteaker P, Bolchi C. Subnanomolar Affinity and Selective Antagonism at α7 Nicotinic Receptor by Combined Modifications of 2-Triethylammonium Ethyl Ether of 4-Stilbenol (MG624). Journal of Medicinal Chemistry. PMID 36526469 DOI: 10.1021/acs.jmedchem.2c01256  0.416
2022 Bavo F, Pallavicini M, Pucci S, Appiani R, Giraudo A, Eaton B, Lucero L, Gotti C, Moretti M, Whiteaker P, Bolchi C. From 2-Triethylammonium Ethyl Ether of 4-Stilbenol (MG624) to Selective Small-Molecule Antagonists of Human α9α10 Nicotinic Receptor by Modifications at the Ammonium Ethyl Residue. Journal of Medicinal Chemistry. 65: 10079-10097. PMID 35834819 DOI: 10.1021/acs.jmedchem.2c00746  0.473
2021 Pisapati AV, Cao W, Anderson KR, Jones G, Holick KH, Whiteaker P, Im W, Zhang XF, Miwa JM. Biophysical characterization of lynx-nicotinic receptor interactions using atomic force microscopy. Faseb Bioadvances. 3: 1034-1042. PMID 34938964 DOI: 10.1096/fba.2021-00012  0.525
2021 Weltzin MM, George AA, Lukas RJ, Whiteaker P. Sleep-related hypermotor epilepsy associated mutations uncover important kinetic roles of α4β2- nicotinic acetylcholine receptor intracellular structures. Plos One. 16: e0247825. PMID 33657187 DOI: 10.1371/journal.pone.0247825  0.434
2020 George AA, Vieira JM, Xavier-Jackson C, Gee MT, Cirrito JR, Bimonte-Nelson H, Picciotto MR, Lukas RJ, Whiteaker P. Implications of oligomeric amyloid-beta (oAβ42) signaling through α7β2-nicotinic acetylcholine receptors (nAChR) on basal forebrain cholinergic neuronal intrinsic excitability and cognitive decline. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33239400 DOI: 10.1523/JNEUROSCI.0876-20.2020  0.351
2019 Liu Q, Li M, Whiteaker P, Shi FD, Morley BJ, Lukas RJ. Attenuation in Nicotinic Acetylcholine Receptor α9 and α10 Subunit Double Knock-Out Mice of Experimental Autoimmune Encephalomyelitis. Biomolecules. 9. PMID 31817275 DOI: 10.3390/biom9120827  0.434
2019 Ma ZG, Jiang N, Huang YB, Ma XK, Brek Eaton J, Gao M, Chang YC, Lukas RJ, Whiteaker P, Neisewander J, Wu J. Cocaine potently blocks neuronal αβ nicotinic acetylcholine receptors in SH-SY5Y cells. Acta Pharmacologica Sinica. PMID 31399700 DOI: 10.1038/S41401-019-0276-Y  0.436
2019 Hone A, Fisher F, Christensen S, Gajewiak J, Larkin D, Whiteaker P, McIntosh JM. PeIA-5466: A novel peptide antagonist containing non-natural amino acids that selectively targets α3β2 nicotinic acetylcholine receptors. Journal of Medicinal Chemistry. PMID 31194549 DOI: 10.1021/Acs.Jmedchem.9B00566  0.504
2019 Weltzin MM, George AA, Lukas RJ, Whiteaker P. Distinctive single-channel properties of α4β2-nicotinic acetylcholine receptor isoforms. Plos One. 14: e0213143. PMID 30845161 DOI: 10.1371/Journal.Pone.0213143  0.535
2019 Chen D, Gao F, Ma X, Eaton JB, Huang Y, Gao M, Chang Y, Ma Z, Der-Ghazarian T, Neisewander J, Whiteaker P, Wu J, Su Q. Cocaine Directly Inhibits α6-Containing Nicotinic Acetylcholine Receptors in Human SH-EP1 Cells and Mouse VTA DA Neurons. Frontiers in Pharmacology. 10: 72. PMID 30837868 DOI: 10.3389/Fphar.2019.00072  0.469
2019 Gao F, Chen D, Ma X, Sudweeks S, Yorgason JT, Gao M, Turner D, Eaton JB, McIntosh JM, Lukas RJ, Whiteaker P, Chang Y, Steffensen SC, Wu J. Alpha6-containing nicotinic acetylcholine receptor is a highly sensitive target of alcohol. Neuropharmacology. PMID 30710570 DOI: 10.1016/J.Neuropharm.2019.01.021  0.557
2018 Chen DJ, Gao FF, Ma XK, Shi GG, Huang YB, Su QX, Sudweeks S, Gao M, Dharshaun T, Eaton JB, Chang YC, Mcintosh JM, Lukas RJ, Whiteaker P, Steffensen SC, et al. Pharmacological and functional comparisons of α6/α3β2β3-nAChRs and α4β2-nAChRs heterologously expressed in the human epithelial SH-EP1 cell line. Acta Pharmacologica Sinica. PMID 29795357 DOI: 10.1038/Aps.2017.209  0.552
2018 Morley BJ, Whiteaker P, Elgoyhen AB. Commentary: Nicotinic Acetylcholine Receptor α9 and α10 Subunits Are Expressed in the Brain of Mice. Frontiers in Cellular Neuroscience. 12: 104. PMID 29765305 DOI: 10.3389/Fncel.2018.00104  0.572
2017 Liu Q, Whiteaker P, Morley BJ, Shi FD, Lukas RJ. Distinctive Roles for α7*- and α9*-Nicotinic Acetylcholine Receptors in Inflammatory and Autoimmune Responses in the Murine Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. Frontiers in Cellular Neuroscience. 11: 287. PMID 29018331 DOI: 10.3389/Fncel.2017.00287  0.541
2017 George AA, Bloy A, Miwa JM, Lindstrom JM, Lukas RJ, Whiteaker P. Isoform-specific mechanisms of α3β4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28100642 DOI: 10.1096/Fj.201600733R  0.596
2016 Wu J, Liu Q, Tang P, Mikkelsen JD, Shen J, Whiteaker P, Yakel JL. Heteromeric α7β2 Nicotinic Acetylcholine Receptors in the Brain. Trends in Pharmacological Sciences. PMID 27179601 DOI: 10.1016/J.Tips.2016.03.005  0.579
2015 Lucero LM, Weltzin MM, Eaton JB, Cooper JF, Lindstrom JM, Lukas RJ, Whiteaker P. Differential α4(+)/(-)β2 Agonist Binding Site Contributions to α4β2 Nicotinic Acetylcholine Receptor Function Within and Between Isoforms. The Journal of Biological Chemistry. PMID 26644472 DOI: 10.1074/Jbc.M115.684373  0.519
2015 Ochoa V, George AA, Nishi R, Whiteaker P. The prototoxin LYPD6B modulates heteromeric α3β4-containing nicotinic acetylcholine receptors, but not α7 homomers. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 26586467 DOI: 10.1096/Fj.15-274548  0.457
2015 Weltzin MM, Lindstrom JM, Lukas RJ, Whiteaker P. Distinctive effects of nicotinic receptor intracellular-loop mutations associated with nocturnal frontal lobe epilepsy. Neuropharmacology. PMID 26561946 DOI: 10.1016/J.Neuropharm.2015.11.004  0.499
2015 Hone AJ, McIntosh JM, Azam L, Lindstrom J, Lucero L, Whiteaker P, Passas J, Blázquez J, Albillos A. α-Conotoxins Identify the α3β4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells. Molecular Pharmacology. 88: 881-93. PMID 26330550 DOI: 10.1124/Mol.115.100982  0.514
2015 Lukas RJ, Liu Q, Lucero L, Simard AR, Whiteaker P, Morley BJ, Shi F. Diverse nicotinic mechanisms in a model of multiple sclerosis Biochemical Pharmacology. 97: 633-634. DOI: 10.1016/J.Bcp.2015.08.036  0.44
2015 George A, Lukas R, Whiteaker P. Differential modulation of α3β4 and α3β4α5 nAChR isoforms by the endogenous neuromodulator lynx1 Biochemical Pharmacology. 97: 628-629. DOI: 10.1016/J.Bcp.2015.08.024  0.416
2015 Weltzin MM, George AA, Lukas RJ, Whiteaker P. Nocturnal frontal lobe epilepsy-associated intracellular-loop mutant subunits alter single-channel properties of α4β2-nicotinic receptor isoforms Biochemical Pharmacology. 97: 628. DOI: 10.1016/J.Bcp.2015.08.023  0.5
2015 Whiteaker P, Kassner M, Eaton JB, Petit J, Meurice N, Yin H. Development and validation of an α3β4 nicotinic acetylcholine receptor (nAChR) high-throughput screening- (HTS-) ready assay Biochemical Pharmacology. 97: 622-623. DOI: 10.1016/J.Bcp.2015.08.009  0.489
2014 Yu LF, Brek Eaton J, Zhang HK, Sabath E, Hanania T, Li GN, van Breemen RB, Whiteaker P, Liu Q, Wu J, Chang YC, Lukas RJ, Brunner D, Kozikowski AP. The potent and selective α4β2*/α6*-nicotinic acetylcholine receptor partial agonist 2-[5-[5-((S)Azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol demonstrates antidepressive-like behavior in animal models and a favorable ADME-tox profile. Pharmacology Research & Perspectives. 2: e00026. PMID 25505580 DOI: 10.1002/Prp2.26  0.465
2014 Moretti M, Zoli M, George AA, Lukas RJ, Pistillo F, Maskos U, Whiteaker P, Gotti C. The novel α7β2-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterization. Molecular Pharmacology. 86: 306-17. PMID 25002271 DOI: 10.1124/Mol.114.093377  0.572
2014 Marks MJ, Grady SR, Salminen O, Paley MA, Wageman CR, McIntosh JM, Whiteaker P. α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration. Journal of Neurochemistry. 130: 185-98. PMID 24661093 DOI: 10.1111/jnc.12721  0.529
2014 Luo S, Zhangsun D, Schroeder CI, Zhu X, Hu Y, Wu Y, Weltzin MM, Eberhard S, Kaas Q, Craik DJ, McIntosh JM, Whiteaker P. A novel α4/7-conotoxin LvIA from Conus lividus that selectively blocks α3β2 vs. α6/α3β2β3 nicotinic acetylcholine receptors. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 1842-53. PMID 24398291 DOI: 10.1096/Fj.13-244103  0.546
2014 Eaton JB, Lucero LM, Stratton H, Chang Y, Cooper JF, Lindstrom JM, Lukas RJ, Whiteaker P. The unique α4+/-α4 agonist binding site in (α4)3(β2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (α4)2(β2)3 subtype. The Journal of Pharmacology and Experimental Therapeutics. 348: 46-58. PMID 24190916 DOI: 10.1124/Jpet.113.208389  0.598
2013 Zhang HK, Yu LF, Eaton JB, Whiteaker P, Onajole OK, Hanania T, Brunner D, Lukas RJ, Kozikowski AP. Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II. Journal of Medicinal Chemistry. 56: 5495-504. PMID 23734673 DOI: 10.1021/Jm400510U  0.431
2013 Hao J, Shi FD, Abdelwahab M, Shi SX, Simard A, Whiteaker P, Lukas R, Zhou Q. Nicotinic Receptor β2 Determines NK Cell-Dependent Metastasis in a Murine Model of Metastatic Lung Cancer Plos One. 8. PMID 23469004 DOI: 10.1371/Journal.Pone.0057495  0.52
2013 Simard AR, Gan Y, St-Pierre S, Kousari A, Patel V, Whiteaker P, Morley BJ, Lukas RJ, Shi FD. Differential modulation of EAE by α9*- and β2*-nicotinic acetylcholine receptors. Immunology and Cell Biology. 91: 195-200. PMID 23399696 DOI: 10.1038/Icb.2013.1  0.546
2013 Talka R, Salminen O, Whiteaker P, Lukas RJ, Tuominen RK. Nicotine-morphine interactions at α4β2, α7 and α3(⁎) nicotinic acetylcholine receptors. European Journal of Pharmacology. 701: 57-64. PMID 23340223 DOI: 10.1016/J.Ejphar.2013.01.005  0.583
2012 Breining SR, Melvin M, Bhatti BS, Byrd GD, Kiser MN, Hepler CD, Hooker DN, Zhang J, Reynolds LA, Benson LR, Fedorov NB, Sidach SS, Mitchener JP, Lucero LM, Lukas RJ, ... Whiteaker P, et al. Structure-activity studies of 7-heteroaryl-3-azabicyclo[3.3.1]non-6-enes: a novel class of highly potent nicotinic receptor ligands. Journal of Medicinal Chemistry. 55: 9929-45. PMID 23025891 DOI: 10.1021/Jm3011299  0.541
2012 George AA, Lucero LM, Damaj MI, Lukas RJ, Chen X, Whiteaker P. Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5(D398N) variant. The Journal of Biological Chemistry. 287: 25151-62. PMID 22665477 DOI: 10.1074/Jbc.M112.379339  0.58
2012 McClure-Begley TD, Wageman CR, Grady SR, Marks MJ, McIntosh JM, Collins AC, Whiteaker P. A novel α-conotoxin MII-sensitive nicotinic acetylcholine receptor modulates [(3) H]-GABA release in the superficial layers of the mouse superior colliculus. Journal of Neurochemistry. 122: 48-57. PMID 22506481 DOI: 10.1111/J.1471-4159.2012.07759.X  0.445
2012 Murray TA, Bertrand D, Papke RL, George AA, Pantoja R, Srinivasan R, Liu Q, Wu J, Whiteaker P, Lester HA, Lukas RJ. α7β2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their α7-α7 interfaces. Molecular Pharmacology. 81: 175-88. PMID 22039094 DOI: 10.1124/Mol.111.074088  0.759
2011 Letchworth SR, Whiteaker P. Progress and challenges in the study of α6-containing nicotinic acetylcholine receptors. Biochemical Pharmacology. 82: 862-72. PMID 21736871 DOI: 10.1016/j.bcp.2011.06.022  0.524
2011 Zhang J, Xue F, Whiteaker P, Li C, Wu W, Shen B, Huang Y, Lukas RJ, Chang Y. Desensitization of alpha7 nicotinic receptor is governed by coupling strength relative to gate tightness. The Journal of Biological Chemistry. 286: 25331-40. PMID 21610071 DOI: 10.1074/Jbc.M111.221754  0.499
2011 Yang K, Buhlman L, Khan GM, Nichols RA, Jin G, McIntosh JM, Whiteaker P, Lukas RJ, Wu J. Functional nicotinic acetylcholine receptors containing α6 subunits are on GABAergic neuronal boutons adherent to ventral tegmental area dopamine neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 2537-48. PMID 21325521 DOI: 10.1523/Jneurosci.3003-10.2011  0.506
2011 Marks MJ, McClure-Begley TD, Whiteaker P, Salminen O, Brown RW, Cooper J, Collins AC, Lindstrom JM. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. The Journal of Pharmacology and Experimental Therapeutics. 337: 187-200. PMID 21228066 DOI: 10.1124/Jpet.110.178236  0.576
2011 Hao J, Simard AR, Turner GH, Wu J, Whiteaker P, Lukas RJ, Shi FD. Attenuation of CNS inflammatory responses by nicotine involves α7 and non-α7 nicotinic receptors. Experimental Neurology. 227: 110-9. PMID 20932827 DOI: 10.1016/J.Expneurol.2010.09.020  0.583
2011 Lucero L, Bhakta M, Liu G, Wu J, Hauser T, Bencherif M, Bermudez I, Whiteaker P, Lukas R. Tethered pentamers—Low sensitivity α4β2-nicotinic acetylcholine receptors Biochemical Pharmacology. 82: 1025. DOI: 10.1016/J.Bcp.2011.07.008  0.598
2011 Whiteaker P, Lucero L, Lukas R, Hepler C, Strachan J, Letchworth S. Construction of cell line heterologously expressing the α6/3β2β3 nicotinic acetylcholine receptor (nAChR) subtype Biochemical Pharmacology. 82: 1024-1025. DOI: 10.1016/J.Bcp.2011.07.007  0.605
2011 Breining SR, Hepler C, Whiteaker P, Quik M, Grady SR, Yohannes D. Comparison of binding and functional activity profiles for a set of nicotinic acetylcholine receptor ligands across multiple α6* expression systems Biochemical Pharmacology. 82: 1024. DOI: 10.1016/J.Bcp.2011.07.006  0.55
2011 Abdrakhmanova G, Simard A, Whiteaker P, Lukas R, Damaj M, Kendler K, Chen X. Functional examination of human α4β2α5 nicotinic AChRs transfected in SH-EP1 cells Biochemical Pharmacology. 82: 1023. DOI: 10.1016/J.Bcp.2011.07.003  0.488
2010 Chang Y, Huang Y, Whiteaker P. Mechanism of Allosteric Modulation of the Cys-loop Receptors. Pharmaceuticals (Basel, Switzerland). 3: 2592-2609. PMID 27713368 DOI: 10.3390/Ph3082592  0.451
2010 Talboom JS, Engler-Chiurazzi EB, Whiteaker P, Simard AR, Lukas R, Acosta JI, Prokai L, Bimonte-Nelson HA. A component of Premarin(®) enhances multiple cognitive functions and influences nicotinic receptor expression. Hormones and Behavior. 58: 917-28. PMID 20849857 DOI: 10.1016/J.Yhbeh.2010.09.002  0.434
2010 Hone AJ, Whiteaker P, Mohn JL, Jacob MH, McIntosh JM. Alexa Fluor 546-ArIB[V11L;V16A] is a potent ligand for selectively labeling alpha 7 nicotinic acetylcholine receptors. Journal of Neurochemistry. 114: 994-1006. PMID 20492354 DOI: 10.1111/J.1471-4159.2010.06819.X  0.551
2010 Grady SR, Drenan RM, Breining SR, Yohannes D, Wageman CR, Fedorov NB, McKinney S, Whiteaker P, Bencherif M, Lester HA, Marks MJ. Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors. Neuropharmacology. 58: 1054-66. PMID 20114055 DOI: 10.1016/J.Neuropharm.2010.01.013  0.533
2010 Zhao-Shea R, Cohen BN, Just H, McClure-Begley T, Whiteaker P, Grady SR, Salminen O, Gardner PD, Lester HA, Tapper AR. Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 49-57. PMID 19720621 DOI: 10.1096/Fj.09-137034  0.561
2010 Marks MJ, Laverty DS, Whiteaker P, Salminen O, Grady SR, McIntosh JM, Collins AC. John Daly's compound, epibatidine, facilitates identification of nicotinic receptor subtypes. Journal of Molecular Neuroscience : Mn. 40: 96-104. PMID 19672723 DOI: 10.1007/S12031-009-9264-X  0.564
2010 Wu J, Liu Q, Whiteaker P, Lukas RJ. P2-296: α7 nicotinic acetylcholine receptors contribute to amyloid-induced neuronal hyperexcitation Alzheimer's & Dementia. 6: S400-S400. DOI: 10.1016/J.Jalz.2010.05.1346  0.541
2009 Hone AJ, Whiteaker P, Christensen S, Xiao Y, Meyer EL, McIntosh JM. A novel fluorescent alpha-conotoxin for the study of alpha7 nicotinic acetylcholine receptors. Journal of Neurochemistry. 111: 80-9. PMID 19650873 DOI: 10.1111/J.1471-4159.2009.06299.X  0.531
2009 Breining SR, Bencherif M, Grady SR, Whiteaker P, Marks MJ, Wageman CR, Lester HA, Yohannes D. Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the alpha6( *) subtype. Bioorganic & Medicinal Chemistry Letters. 19: 4359-63. PMID 19560354 DOI: 10.1016/J.Bmcl.2009.05.085  0.577
2009 Murray TA, Liu Q, Whiteaker P, Wu J, Lukas RJ. Nicotinic acetylcholine receptor alpha7 subunits with a C2 cytoplasmic loop yellow fluorescent protein insertion form functional receptors. Acta Pharmacologica Sinica. 30: 828-41. PMID 19498423 DOI: 10.1038/Aps.2009.78  0.763
2009 Whiteaker P, Wilking JA, Brown RW, Brennan RJ, Collins AC, Lindstrom JM, Boulter J. Pharmacological and immunochemical characterization of alpha2* nicotinic acetylcholine receptors (nAChRs) in mouse brain. Acta Pharmacologica Sinica. 30: 795-804. PMID 19498420 DOI: 10.1038/Aps.2009.68  0.491
2009 Collins AC, Salminen O, Marks MJ, Whiteaker P, Grady SR. The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handbook of Experimental Pharmacology. 85-112. PMID 19184647 DOI: 10.1007/978-3-540-69248-5_4  0.617
2009 Zheng C, Wang MY, Liu Q, Wakui M, Whiteaker P, Lukas RJ, Wu J. U18666A, a cholesterol-inhibition agent, modulates human neuronal nicotinic acetylcholine receptors heterologously expressed in SH-EP1 cell line. Journal of Neurochemistry. 108: 1526-38. PMID 19183258 DOI: 10.1111/J.1471-4159.2009.05903.X  0.584
2009 Yang K, Buhlman L, Gao M, Khan GM, Nichols RA, DeChon J, Jin G, Whiteaker P, Lukas RJ, Wu J. Functional presynaptic α6-containing nicotinic acetylcholine receptors participate in nicotine reward in the VTA: where and how Nature Precedings. DOI: 10.1038/Npre.2009.2875.1  0.617
2009 Hone AJ, Mohn JL, Jacob M, Whiteaker P, McIntosh JM. Labeling α7 nAChRs on hippocampal neurons using fluorescent analogs of α-conotoxin ArIB[V11L;V16A] Biochemical Pharmacology. 78: 903. DOI: 10.1016/J.Bcp.2009.06.039  0.407
2009 Dash B, Bhakta M, Whiteaker P, Stizel JA, Chang Y, Lukas RJ. Gain of function mutants in human or mouse nAChR β3 subunits interchangeably activate either human or mouse α6β4*-nAChR, but not human or mouse α6β2*-nAChR Biochemical Pharmacology. 78: 901-902. DOI: 10.1016/J.Bcp.2009.06.036  0.435
2008 Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors. Neuron. 60: 123-36. PMID 18940593 DOI: 10.1016/J.Neuron.2008.09.009  0.565
2008 Innocent N, Livingstone PD, Hone A, Kimura A, Young T, Whiteaker P, McIntosh JM, Wonnacott S. Alpha-conotoxin Arenatus IB[V11L,V16D] [corrected] is a potent and selective antagonist at rat and human native alpha7 nicotinic acetylcholine receptors. The Journal of Pharmacology and Experimental Therapeutics. 327: 529-37. PMID 18664588 DOI: 10.1124/Jpet.108.142943  0.534
2008 Whiteaker P, Marks MJ, Christensen S, Dowell C, Collins AC, McIntosh JM. Synthesis and characterization of 125I-alpha-conotoxin ArIB[V11L;V16A], a selective alpha7 nicotinic acetylcholine receptor antagonist. The Journal of Pharmacology and Experimental Therapeutics. 325: 910-9. PMID 18323456 DOI: 10.1124/Jpet.108.136895  0.518
2007 Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. Biochemical Pharmacology. 74: 1235-46. PMID 17825262 DOI: 10.1016/J.Bcp.2007.07.032  0.647
2007 Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, Collins AC, Marks MJ, Lester HA. Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 8202-18. PMID 17670967 DOI: 10.1523/Jneurosci.2199-07.2007  0.627
2007 Brown RW, Collins AC, Lindstrom JM, Whiteaker P. Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. Journal of Neurochemistry. 103: 204-15. PMID 17573823 DOI: 10.1111/J.1471-4159.2007.04700.X  0.67
2007 Whiteaker P, Christensen S, Yoshikami D, Dowell C, Watkins M, Gulyas J, Rivier J, Olivera BM, McIntosh JM. Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist. Biochemistry. 46: 6628-38. PMID 17497892 DOI: 10.1021/Bi7004202  0.527
2006 Whiteaker P, Cooper JF, Salminen O, Marks MJ, McClure-Begley TD, Brown RW, Collins AC, Lindstrom JM. Immunolabeling demonstrates the interdependence of mouse brain alpha4 and beta2 nicotinic acetylcholine receptor subunit expression. The Journal of Comparative Neurology. 499: 1016-38. PMID 17072836 DOI: 10.1002/Cne.21181  0.453
2006 Marks MJ, Whiteaker P, Collins AC. Deletion of the alpha7, beta2, or beta4 nicotinic receptor subunit genes identifies highly expressed subtypes with relatively low affinity for [3H]epibatidine. Molecular Pharmacology. 70: 947-59. PMID 16728647 DOI: 10.1124/Mol.106.025338  0.469
2005 Fonck C, Cohen BN, Nashmi R, Whiteaker P, Wagenaar DA, Rodrigues-Pinguet N, Deshpande P, McKinney S, Kwoh S, Munoz J, Labarca C, Collins AC, Marks MJ, Lester HA. Novel seizure phenotype and sleep disruptions in knock-in mice with hypersensitive alpha 4* nicotinic receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 11396-411. PMID 16339034 DOI: 10.1523/Jneurosci.3597-05.2005  0.427
2005 Gotti C, Moretti M, Zanardi A, Gaimarri A, Champtiaux N, Changeux JP, Whiteaker P, Marks MJ, Clementi F, Zoli M. Heterogeneity and selective targeting of neuronal nicotinic acetylcholine receptor (nAChR) subtypes expressed on retinal afferents of the superior colliculus and lateral geniculate nucleus: identification of a new native nAChR subtype alpha3beta2(alpha5 or beta3) enriched in retinocollicular afferents. Molecular Pharmacology. 68: 1162-71. PMID 16049166 DOI: 10.1124/Mol.105.015925  0.576
2005 Salminen O, Whiteaker P, Grady SR, Collins AC, McIntosh JM, Marks MJ. The subunit composition and pharmacology of alpha-Conotoxin MII-binding nicotinic acetylcholine receptors studied by a novel membrane-binding assay. Neuropharmacology. 48: 696-705. PMID 15814104 DOI: 10.1016/J.Neuropharm.2004.12.011  0.564
2005 Gotti C, Moretti M, Clementi F, Riganti L, McIntosh JM, Collins AC, Marks MJ, Whiteaker P. Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion. Molecular Pharmacology. 67: 2007-15. PMID 15749993 DOI: 10.1124/mol.105.011940  0.409
2005 Lai A, Parameswaran N, Khwaja M, Whiteaker P, Lindstrom JM, Fan H, McIntosh JM, Grady SR, Quik M. Long-term nicotine treatment decreases striatal alpha 6* nicotinic acetylcholine receptor sites and function in mice. Molecular Pharmacology. 67: 1639-47. PMID 15681595 DOI: 10.1124/Mol.104.006429  0.639
2004 Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science (New York, N.Y.). 306: 1029-32. PMID 15528443 DOI: 10.1126/Science.1099420  0.594
2004 McIntosh JM, Azam L, Staheli S, Dowell C, Lindstrom JM, Kuryatov A, Garrett JE, Marks MJ, Whiteaker P. Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors. Molecular Pharmacology. 65: 944-52. PMID 15044624 DOI: 10.1124/Mol.65.4.944  0.538
2003 Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ, Salminen O, Tritto T, Butt CM, Allen WR, Stitzel JA, McIntosh JM, Boulter J, Collins AC, Heinemann SF. The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 11045-53. PMID 14657161  0.5
2003 Quik M, Bordia T, Okihara M, Fan H, Marks MJ, McIntosh JM, Whiteaker P. L-DOPA treatment modulates nicotinic receptors in monkey striatum. Molecular Pharmacology. 64: 619-28. PMID 12920198 DOI: 10.1124/Mol.64.3.619  0.473
2003 Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio J, McIntosh JM, Collins AC, Grady SR. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Molecular Pharmacology. 63: 1169-79. PMID 12695545 DOI: 10.1124/Mol.63.5.1169  0.543
2003 Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ, Salminen O, Tritto T, Butt CM, Allen WR, Stitzel JA, McIntosh JM, Boulter J, Collins AC, Heinemann SF. The β3 Nicotinic Receptor Subunit: A Component of α-Conotoxin MII-Binding Nicotinic Acetylcholine Receptors that Modulate Dopamine Release and Related Behaviors The Journal of Neuroscience. 23: 11045-11053. DOI: 10.1523/Jneurosci.23-35-11045.2003  0.62
2002 Dobelis P, Marks MJ, Whiteaker P, Balogh SA, Collins AC, Stitzel JA. A polymorphism in the mouse neuronal alpha4 nicotinic receptor subunit results in an alteration in receptor function. Molecular Pharmacology. 62: 334-42. PMID 12130686 DOI: 10.1124/Mol.62.2.334  0.581
2002 Mogg AJ, Whiteaker P, McIntosh JM, Marks M, Collins AC, Wonnacott S. Methyllycaconitine is a potent antagonist of alpha-conotoxin-MII-sensitive presynaptic nicotinic acetylcholine receptors in rat striatum. The Journal of Pharmacology and Experimental Therapeutics. 302: 197-204. PMID 12065717 DOI: 10.1124/Jpet.302.1.197  0.542
2002 Marks MJ, Whiteaker P, Grady SR, Picciotto MR, McIntosh JM, Collins AC. Characterization of [(125) I]epibatidine binding and nicotinic agonist-mediated (86) Rb(+) efflux in interpeduncular nucleus and inferior colliculus of beta2 null mutant mice. Journal of Neurochemistry. 81: 1102-15. PMID 12065623 DOI: 10.1046/J.1471-4159.2002.00910.X  0.546
2002 Whiteaker P, Peterson CG, Xu W, McIntosh JM, Paylor R, Beaudet AL, Collins AC, Marks MJ. Involvement of the alpha3 subunit in central nicotinic binding populations. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 2522-9. PMID 11923417  0.463
2002 Whiteaker P, Peterson CG, Xu W, McIntosh JM, Paylor R, Beaudet AL, Collins AC, Marks MJ. Involvement of the α3 Subunit in Central Nicotinic Binding Populations The Journal of Neuroscience. 22: 2522-2529. DOI: 10.1523/Jneurosci.22-07-02522.2002  0.537
2000 Whiteaker P, Jimenez M, McIntosh JM, Collins AC, Marks MJ. Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. British Journal of Pharmacology. 131: 729-39. PMID 11030722 DOI: 10.1038/Sj.Bjp.0703616  0.446
2000 Whiteaker P, Marks MJ, Grady SR, Lu Y, Picciotto MR, Changeux JP, Collins AC. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. European Journal of Pharmacology. 393: 123-35. PMID 10771005 DOI: 10.1016/S0014-2999(00)00052-2  0.592
2000 Sharples CG, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, Spencer JA, Gallagher T, Whiteaker P, Wonnacott S. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 2783-91. PMID 10751429  0.481
2000 Sharples CGV, Kaiser S, Soliakov L, Marks MJ, Collins AC, Washburn M, Wright E, Spencer JA, Gallagher T, Whiteaker P, Wonnacott S. UB-165: A Novel Nicotinic Agonist with Subtype Selectivity Implicates the α4β2* Subtype in the Modulation of Dopamine Release from Rat Striatal Synaptosomes The Journal of Neuroscience. 20: 2783-2791. DOI: 10.1523/Jneurosci.20-08-02783.2000  0.497
1999 Whiteaker P, Davies AR, Marks MJ, Blagbrough IS, Potter BV, Wolstenholme AJ, Collins AC, Wonnacott S. An autoradiographic study of the distribution of binding sites for the novel alpha7-selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. The European Journal of Neuroscience. 11: 2689-96. PMID 10457165 DOI: 10.1046/J.1460-9568.1999.00685.X  0.499
1998 Whiteaker P, Sharples CG, Wonnacott S. Pharmacology of nicotinic acetylcholine receptor (nAChR) upregulation in the transfected cell line, M10. Biochemical Society Transactions. 25: 550S. PMID 9388764 DOI: 10.1042/BST025550S  0.47
1995 Whiteaker P, Garcha HS, Wonnacott S, Stolerman IP. Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats British Journal of Pharmacology. 116: 2097-2105. PMID 8640351 DOI: 10.1111/J.1476-5381.1995.Tb16417.X  0.442
Show low-probability matches.